Long-Term Follow-Up of Neuroblastoma-Associated Opsoclonus-Myoclonus-Ataxia Syndrome

Abstract

Objective: The aim of this study is to describe the long-term neurological, neuropsychological and neuroradiological sequelae and to determine prognostic factors for neurological outcome in children with neuroblastoma-associated opsoclonus-myoclonus-ataxia (OMA) syndrome.

Methods: Data on medical history were collected for the study patients. Examinations with grading of neurological signs, neuropsychological tests and brain magnetic resonance imaging with spectroscopy were performed during a follow-up clinic.

Results: Fourteen subjects entered the study. All had localized neuroblastoma and they were evaluated after a median of 7.8 years. Patients with a chronic/multiphasic neurological course received steroids combined with intravenous immunoglobulins in the majority of cases. 71% presented neurological sequelae and 62% had a full-scale IQ below the normal range. All patients showed at least some deficit in the neuropsychological functions assessed (language, visual-motor integration, memory, attention and motor ability). Long-term deficits were more frequently detected in patients with an interval of more than 2 months between OMA onset and its diagnosis, even if in most comparisons statistical significance was not reached. Cerebellar atrophy, observed in 36% of patients, was not associated with the neurological outcome.

Conclusions: Persisting disability is present in most children with neuroblastoma-associated OMA. However, our results support the role of an early diagnosis of OMA in reducing sequelae and encourage the use of new immunosuppressive therapies.

ataxia - cerebellum - neuroblastoma - opsoclonus-myoclonus syndrome - paraneoplastic syndromes

References

• 1 Achenbach TM. Manual for the Child Behavior Checklist/4-18 and 1991 Profile. Burlington, VT: University of Vermont, Department of Psychiatry 1991
• 2 Beery KE. VMI: Developmental Test of Visual-Motor Integration. Firenze: Organizzazioni Speciali 2000
• 3 Bisiacchi PS, Cendron M, Gugliotta M. et al .BVN 5–11: Batteria di Valutazione Neuropsicologica per l’Età Evolutiva. Trento: Erickson 2005
• 4 Blaes F, Jauss M, Kraus J. et al . Adult paraneoplastic opsoclonus-myoclonus syndrome associated with antimitochondrial autoantibodies.  J Neurol Neurosurg Psychiatry. 2003;  74 1595-1596
• 5 Blaes F, Fühlhuber V, Korfei MK. et al . Surface-binding autoantibodies to cerebellar neurons in opsoclonus syndrome.  Ann Neurol. 2005;  58 313-317
• 6 Bortolini U. PFLI: Prove per la valutazione fonologica del linguaggio infantile. Padova: Edit Master 1995
• 7 Brodeur GM, Seeger RC, Barrett A. et al . International criteria for diagnosis, staging, and response to treatment in patients with neuroblastoma.  J Clin Oncol. 1988;  6 1874-1881
• 8 Bulgheroni S, Nichelli F, Riva D. Studio evolutivo dell’attenzione selettiva visiva con l’utilizzo di un test di cancellazione.  Giornale di Neuropsichiatria dell’ Età Evolutiva. 2001;  21 343-356
• 9 Chilosi AM, Cipriani P. Test di Comprensione Grammaticale per Bambini (TCGB). Pisa: Edizioni del Cerro 1995
• 10 Griffiths R. Griffiths Mental Development Scales (GMDS). Firenze: Organizzazioni Speciali 1987
• 11 Hayward K, Jermy RJ, Jenkins SJ. et al . Long-term neurobehavioral outcomes in children with neuroblastoma and opsoclonus-myoclonus-ataxia Syndrome: Relationship to MRI findings and anti-neuronal antibodies.  J Pediatr. 2001;  139 552-559
• 12 Klein A, Schmitt B, Boltshauser E. Long-term outcome of ten children with opsoclonus-myoclonus syndrome.  Eur J Pediatr. 2007;  166 359-363
• 13 Matthay K, Blaes F, Hero B. et al . Opsoclonus myoclonus syndrome in neuroblastoma; a report from a workshop on the dancing eyes syndrome at the advances in neuroblastoma meeting in Genoa, Italy, 2004.  Cancer Lett. 2004;  228 275-282
• 14 Mitchell WG, Davalos-Gonzales Y, Brumm VL. et al . Opsoclonus-ataxia caused by childhood neuroblastoma: Developmental and neurologic sequelae.  Pediatrics. 2002;  109 86-98
• 15 Mitchell WG, Brumm VL, Azen CZ. et al . Longitudinal neurodevelopmental evaluation of children with opsoclonus-ataxia.  Pediatrics. 2005;  116 901-907
• 16 Orsini A, Grossi D, Capitani E. et al . Verbal and spatial immediate memory span: normative data from 1355 adults and 1112 children.  It J Neurol Sci. 1987;  8 539-548
• 17 Papero PH, Pranzatelli MR, Margolis LJ. et al . Neurobehavioral and psychosocial functioning of children with opsoclonus-myoclonus sindrome.  Dev Med Child Neurol. 1995;  37 915-932
• 18 Pranzatelli MR, Tate ED, Kinsbourne M. et al . Forty-one-year follow-up of childhood-onset opsoclonus-myoclonus-ataxia: cerebellar atrophy, multiphasic relapses, and response to IVIg.  Mov Disord. 2002;  17 1387-1390
• 19 Pranzatelli MR, Tate ED, Travelstead AL. et al . Rituximab (anti-CD20) adjunctive therapy for opsoclonus-myoclonus syndrome.  J Pediatr Hematol Oncol. 2006;  28 585-593
• 20 Rostásy K, Wilken B, Baumann M. et al . High dose pulsatile dexamethasone therapy in children with opsoclonus-myoclonus syndrome.  Neuropediatrics. 2006;  37 291-295
• 21 Russo C, Cohn SL, Petruzzi MJ. et al . Long-term neurologic outcome in children with opsoclonus-myoclonus associated with neuroblastoma: A report from the Pediatric Oncology Group.  Med Pediatr Oncol. 1997;  28 284-288
• 22 Schmahmann JD, Sherman JC. The cerebellar cognitive affective syndrome.  Brain. 1998;  121 561-579
• 23 Stella G, Pizzioli C, Tressoldi PE. Peabody – Test di vocabolario recettivo. Torino: OMEGA 2000
• 24 Tate ED, Allison TJ, Pranzatelli MR. et al . Neuroepidemiologic trends in 105 US cases of pediatric opsoclonus-myoclonus syndrome.  J Pediatr Oncol Nurs. 2005;  22 8-19
• 25 Trotti A, Colevas AD, Setser A. et al . CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment.  Semin Radiat Oncol. 2003;  13 176-181
• 26 Tuchman RF, Alvarez LA, Kantrowitz AB. et al . Opsoclonus-myoclonus syndrome: Correlation of radiographic and pathological observations.  Neuroradiology. 1989;  31 250-252
• 27 Wechsler D. Wechsler Preschool and Primary Scale of Intelligence (WPPSI). Firenze: Organizzazioni Speciali 1973
• 28 Wechsler D. Wechsler Intelligence Scale for Children-III (WISC-III). Firenze: Organizzazioni Speciali 2006
• 29 Wilken B, Baumann M, Bien CG. et al . Chronic relapsing opsoclonus-myoclonus syndrome: Combination of cyclophosphamide and dexamethasone pulses.  Eur J Paediatr Neurol. 2008;  12 51-55
• 30 Zucchi M, Giuganino BM, Stella L. Adattamento italiano della scala di sviluppo motorio di Oseretzky. Firenze: Organizzazioni Speciali 1982

Correspondence